Talphera, Inc. (TLPH)
| Market Cap | 45.02M +442.4% |
| Revenue (ttm) | 28,000 |
| Net Income | -14.29M |
| EPS | -0.34 |
| Shares Out | 51.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 234,106 |
| Open | 0.9043 |
| Previous Close | 0.9037 |
| Day's Range | 0.8485 - 0.9242 |
| 52-Week Range | 0.3800 - 1.5700 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+245.82%) |
| Earnings Date | May 13, 2026 |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Feds... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for TLPH stock is "Strong Buy" and the 12-month stock price target is $3.0.
News
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Talphera initiated with a Buy at WestPark Capital
WestPark Capital analyst Ed Arce initiated coverage of Talphera (TLPH) with a Buy rating and $3 price target The firm says the company is brining the best continuous renal replacement…
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera files to sell 639,931 shares of common stock for holders
06:03 EDT Talphera (TLPH) files to sell 639,931 shares of common stock for holders
Talphera Earnings Call Transcript: Q4 2025
The Nephro CRRT study reached 50% enrollment, unlocking $4.1M in financing and progressing toward FDA approval for Niyad. Experts highlight significant operational and safety limitations with current CRRT anticoagulants, anticipating that Niyad could become the preferred option due to its simplicity and effectiveness.
Talphera reports Q4 EPS (6c) vs. (7c) last year
Reports cash and investments of $20.4M at December 31, 2025. “Earlier this month, we communicated reaching the 35-patient enrollment mark in the 70-patient nafamostat registrational study for CRRT. Si...
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to e...
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera announces 50% patient enrollment of the NEPHRO-CRRT clinical trial
Talphera (TLPH) announced 50% patient enrollment of the NEPHRO-CRRT clinical trial. “Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinica...
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET fe...
Talphera Earnings Call Transcript: Q3 2025
NEPHRO study enrollment accelerated after protocol changes, but delays in activating new high-volume sites have shifted expected completion to H1 2026. Cash position and recent financing provide runway through anticipated Niyad PMA approval, with operating expenses reduced year-over-year.
Talphera reports Q3 EPS (11c) vs. (13c) last year
Reports Q3 revenue $1K vs. $0 last year. “The financing closed in September, led by a strategic investment from CorMedix, combined with future conditional tranches, is expected to provide us…
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of...
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
SAN MATEO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
Talphera files to sell 1.02M shares of common stock for holders
The company is not selling any of its common stock pursuant to this prospectus, and will not receive any proceeds from the sale of its common stock offered by this…
Talphera Announces the Appointment of Joe Todisco to Board of Directors
SAN MATEO, Calif. , Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...
Talphera files to sell 25.04M shares of common stock for holders
Also files to sell 5.85M shares of common stock issuable upon exercise of pre-funded warrants for holders.
CorMedix makes $5M minority equity investment in Talphera
CorMedix (CRMD) made a $5M strategic minority equity investment in Talphera, (TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera’s concurrently announced pr...
CorMedix Announces Strategic Minority Investment in Talphera
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for lif...
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million...
Talphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trial
Talphera (TLPH) announced the enrollment of 17 patients in its 70-patient pivotal NEPHRO CRRT clinical trial. The enrollment of 17 patients is a milestone that was required to be achieved,…
Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial
The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study complet...
Talphera Earnings Call Transcript: Q2 2025
NEPHRO study enrollment accelerated with new site strategy, reducing study size and operating expenses. Cash and expected financing should fund operations through study completion, with strong market demand for Nafamostat amid ongoing heparin and citrate shortages.
Talphera reports Q2 EPS (10c) vs. (15c) last year
Cash and cash equivalents at June 30, 2025 were $6.8M. “We have enrolled 15 patients in the NEPHRO clinical study and based on the recent accelerated rate of enrollment, we…
Talphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19M
16:12 EDT Talphera (TLPH) lowers 2025 cash operating expense view to $16M-$17M from $17M-$19M